Evidence map›Paper›PMID 35673584›Full record

ArticleIn silico pharmacology2022

Investigation of the mechanism of Shen Qi Wan prescription in the treatment of T2DM via network pharmacology and molecular docking.

Piaopiao Zhao, Xiaoxiao Zhang, Yuning Gong, Weihua Li, Zengrui Wu, Yun Tang, Guixia Liu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In silico pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Piaopiao ZhaoShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 200237 Shanghai, China.
Xiaoxiao ZhangShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 200237 Shanghai, China.
Yuning GongShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 200237 Shanghai, China.
Weihua LiShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 200237 Shanghai, China.
Zengrui WuShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 200237 Shanghai, China.
Yun TangShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 200237 Shanghai, China.
Guixia LiuShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 200237 Shanghai, China.ORCID 0000-0003-1134-5007
East China University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Shen Qi Wan (SQW) prescription has been used to treat type 2 diabetes mellitus (T2DM) for thousands of years, but its pharmacological mechanism is still unclear. The network pharmacology method was used to reveal the potential pharmacological mechanism of SQW in the treatment of T2DM in this study. Nine core targets were identified through protein-protein interaction (PPI) network analysis and KEGG pathway enrichment analysis, which were AKT1, INSR, SLC2A1, EGFR, PPARG, PPARA, GCK, NOS3, and PTPN1. Besides, this study found that SQW treated the T2DM through insulin resistance (has04931), insulin signaling pathway (has04910), adipocytokine signaling pathway (has04920), AMPK signaling pathway (has04152) and FoxO signaling pathway (has04068) via ingredient-hub target-pathway network analysis. Finally, molecular docking was used to verify the drug-target interaction network in this research. This study provides a certain explanation for treating T2DM by SQW prescription, and provides a certain angle and method for researchers to study the mechanism of TCM in the treatment of complex diseases. Supplementary information: The online version contains supplementary material available at 10.1007/s40203-022-00124-2.

Indexed as

Molecular dockingNetwork pharmacologySQWType 2 diabetes mellitus

Identifiers

PMID35673584
PMCPMC9167366
OpenAlexW4281932332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.